手机管家官方正版
Press Release
  • Press Release
  • Contact Us
  • CStone to present results of translational research in tumor immunity at AACR annual conference

    Date:2018.04.09   Author:CStone

    CStone Pharmaceuticals Co., Ltd (CStone), a biopharmaceutical company focused on development of next-generation innovative drugs, has been invited to present an abstract describing research into the molecular and immunological mechanisms affecting immune checkpoint inhibitor therapy at the 2018 American Association for Cancer Research (AACR) Annual Meeting, to be held in Chicago, Illinois, the United States, April 14-18.


    The AACR's Annual Meeting brings together oncologists, scientists, medical professionals, and patients to present current practices and techniques in the field of cancer prevention and treatment. CStone’s Director of Translational Science Dr. Ying Pan will present Integrative Genome-Scale Analysis of TCGA Dataset for Features of Tumor Immunity during the meeting’s morning Poster Session on April 16.


    CStone, supported by Contract Research Organization (CRO) Crown Biosciences, carried out an integrative genome-scale analysis across a dataset of 9,338 tumors from 24 different cancers. The aim was to explore variations in inflammatory status within the tumor microenvironment (TME) and correlations with immune response. In total nine representative biomarkers were assessed according to T-cell inflamed and non-inflamed tumor subtypes, with the aim of identifying prognostic significance and potential impact on administration of immune checkpoint inhibitor (ICI) therapies. The research revealed that patients with more inflamed TME have significantly longer overall survival in lung adenocarcinoma, liver hepatocellular carcinoma, colon adenocarcinoma and head and neck squamous cell carcinoma. Among other key findings, a high tumor mutation burden (TMB) did not necessarily correlate with a tumor's inflammatory status, and innate anti-PD1 resistance (IPRES) gene signature was found to have limited value as a pan-cancer predictive biomarker. The data-set was derived from the Cancer Genome Atlas (TCGA) database.


    CStone is building an in-house bioinformatics team at its Translational Medicine Research Center (TMRC) in Suzhou that plans to carry out further studies using publicly available datasets and CStone's clinical trial-derived next-generation sequencing data. Dr. Jon Wang, Senior VP, Scientific Affairs, head of TMRC commented: "Our aim is to be at the forefront of understanding of predictive biomarkers to better support clinical trial design, and ultimately to ensure that patients benefit from the right therapy or combination therapy, and also proper sequence and timing of therapy".


    About CStone Pharmaceuticals Co., Ltd

    CStone Pharmaceuticals is a biopharmaceutical company devoted to the development of next-generation innovative drugs. With its broad immuno-oncology pipeline, the firm is pursuing a development strategy focused on combination therapy. In July 2016, CStone announced the completion of its $150 million Series A financing, led by three prestigious VC/PE funds: Oriza Seed Venture Capital, Boyu Capital, and WuXi Healthcare Ventures. All members of the management team are seasoned executives from top multinational pharmaceutical companies. CStone has successfully built up an industry leading team with clinical development and translational medicine as its core competence. With funding and pipeline, CStone is well positioned as the partner of choice for multinational pharmaceutical / biotech companies to develop drugs in China and the Asia-Pacific region.


    For more information about CStone Pharmaceuticals, please visit: http:/

    Your privacy is important for us. We use cookies to enhance your experience when visiting our websites: performance cookies show us how you use this website, functional cookies remember your preferences and targeting cookies help us to share content relevant to you. Select “Accept all” for giving your consent to all cookies or select “Reject all” for using only strictly necessary cookies.